Canadian Reimbursement and Forecasting Timelines (CRaFT) Report

April 2022 Edition

WHY DO YOU NEED THIS REPORT?

The Canadian Reimbursement and Forecasting Timelines (CRaFT) Report April 2022 Edition is a 100+ page PowerPoint resource complete with analysis and insights from trusted industry experts.

MORSE analyzed Canadian market access data to create key reimbursement metrics. The Report can support any organization that is planning a Canadian launch by providing critical timeline insights on the public market reimbursement process – from HTA submission to provincial funding.

WHAT DOES THE REPORT INCLUDE?

  • CADTH volume & timeline metrics
  • pCPA volume & timeline metrics
  • pCPA negotiation trends
  • pCPA Developments – Targeted Negotiation Process
  • Provincial funding volume & timeline metrics
  • Market access timeline forecasting (from HTA submission to first funding)
  • Sub-analysis of data with stratification by Oncology, Non-Oncology, Biosimilars, and Others

The Report focuses on metrics from 2021 but also provides relevant comparisons to 2018-2020 to identify trends. In addition, it contains formulary funding information from 2019-2021 pCPA Completed Negotiations (current as of January 31st, 2022).

FEEDBACK ON THIS REPORT

"This report is highly regarded in the industry.  I sit on one of the IMC operational committees, where we often discuss access to therapies.  In speaking with a colleague from [MFR], he mentioned that his company also purchases the CRaFT report. Lately, I have referenced the CRaFT report to help support discussions on access to drugs in certain provinces." 

– Patient Access and Government Affairs Manager
Toronto-based Pharmaceutical Company

"The Canadian Reimbursement and Forecasting Timelines (CRaFT) report is a critical tool that we leverage in Canadian oncology market access discussions with Global teams as well as forecasting. The report provides objective data and timelines with each step throughout the entire reimbursement process, identifies key trends, and summarizes information in an easy-to-read format. I would highly recommend this report if you are looking for a comprehensive overview of the current Canadian reimbursement landscape."

– Director, Market Access
Toronto-Based Pharmaceutical Company

NEW! DRUGS FOR RARE DISEASES (DRD) SUB-REPORT

Designed to accompany MORSE’s Canadian Reimbursement and Forecasting Timelines (CRaFT) Report, the Drugs for Rare Diseases (DRD) Sub-Report offers credible, relevant insights related to DRD files to support a company’s reimbursement forecasting needs.

OTHER SUB-REPORTS

For further information on content and pricing, please complete the form below.

This report is only available to pharmaceutical companies to assist with their reimbursement forecasting and planning.


We're committed to your privacy. MORSE may use the information you provide to us to contact you about our relevant content and services. Your name, address and all other personal information will not be sold or given to any other organization or list distributor. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

Canadian Reimbursement and Forecasting Timelines Report44, October 2021 Update